This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main objective of this open-label trial is to demonstrate and confirm the safety and effectiveness of Fabrazyme in patients with Fabry disease. Participants will be eligible for the study only if they were enrolled and completed the AGAL-008-00 study for which we are currently a study site. The primary objective is to evaluate the stabilization of renal function with Fabrazyme by means of estimating the difference within the placebo patients' inverse serum creatinine slope while in the study AGAL-008-00 versus the inverse serum creatinine slope while in the open label extension study (AGAL02503).
Showing the most recent 10 out of 502 publications